Get started
Author

Leona Knox

Observed names: Knox, Leona, Leona J. Knox
ORCID: 0000-0002-5218-3895
Observed ORCID: 0000-0002-5218-3895
OpenAlex ID: A5085868479
ACCELERATE – Five years accelerating cancer drug development for children and adolescents
2022 · Andrew D.J. Pearson, Susan L. Weiner, et al. · European Journal of Cancer · 54
PDF
Pediatric cancer research: Surviving COVID‐19
2020 · Jeffery J. Auletta, Peter C. Adamson, et al. · Pediatric Blood & Cancer · 35
PDF
Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE
2021 · Teresa de Rojas, Andrew J. Pearson, et al. · Cancer Medicine · 20
PDF
When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma
2021 · Nicholas Bird, Leona Knox, et al. · Journal of Clinical Oncology · 16
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
2025 · Steven G. DuBois, Lucas Moreno, et al. · Pediatric Blood & Cancer · 15
PDF
Integration of patient and public involvement in a doctoral research study using the research cycle
2024 · Helen Pearson, Carol Bell, et al. · Research Involvement and Engagement · 14
PDF
Changing incentives to ACCELERATE drug development for paediatric cancer
2023 · Teresa de Rojas, Pamela Kearns, et al. · Cancer Medicine · 13
PDF
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
2025 · Andrew D J Pearson, Claudia Rossig, et al. · The Lancet Oncology · 12
The RACE to accelerate drug development for children with cancer
2020 · Andrew D J Pearson, Dominik Karres, et al. · The Lancet Child & Adolescent Health · 8
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better
2025 · Peter J. Gawne, Helen E. Bryant, et al. · Journal of Nuclear Medicine · 6
PDF
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
2025 · Andrew DJ Pearson, Susan Chi, et al. · European Journal of Cancer · 5
A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma
2025 · Lucas Moreno, Steven G. Dubois, et al. · Pediatric Blood & Cancer · 4
Patients, parents and professional perspectives on molecular radiotherapy for neuroblastoma and paediatric neuroendocrine cancers
2025 · Lisa Whittaker, Leona Knox, et al. · Nuclear Medicine Communications · 2
Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers
2024 · Nicholas Bird, Nicole Scobie, et al. · JAMA Network Open · 2
PDF
Role of Patients and Advocates in Cancer Therapeutics Development
2022 · Donna Ludwinski, Nicole Scobie, et al. · Pediatric oncology · 1
Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium
2026 · Uri Ilan, Alba Rubio-San-Simón, et al. · European Journal of Cancer
Works count: 19
Citation count: 207
H-index: 8
I10-index: 8
Year
Topic
Type